OREANDA-NEWS. January 21, 2013. ‘Kanarb’, a new ARB medicine for high blood pressure developed by Boryung Pharmaceutical Company is gaining momentum in entering global market. That’s because success in entering European market for the first time after the market entrance in Latin America and Brazil. Boryung Pharm. Co. announced on January 7th that they reached an agreement with R-Pharm. Co. from Russia to export new high blood pressure medicine ‘Kanarb’ after signing contacts with 13 Latin America countries including Mexico and Brazil.

Boryung Pharm. Co. will grant “R-Pharm” Co. the agreement on selling new medicine “Kanarb (Fimasartan) for high blood pressure in Russia and supplying ‘Kanarb’ mono. Boryung Pharm. Co. anticipates this Kanarb agreement as a first step in entering European market.

“Cardiovascular pathology is considered a serious problem of modern society due to its negative effect on public morbidity and mortality rates. Arterial hypertension is one of the most important cardiovascular diseases. Healthcare community pays significant attention to the treatment of hypertension, but this disease still has high rate of incidence. Stroke and myocardial infarction are among the most severe sequels of arterial hypertension. Accessibility of the drug in Russia will play a positive role in reduction of mortality rate of hypertension-related diseases,” said “R-Pharm” representative.

“This entry in Russian market in succession of 13 countries of Latin America, and Brazil is a stepping stone in entering European market and a meaningful achievement in becoming a global medicine”, “We are looking to enter Chinese market early this year and this will make a fine example in terms of becoming success of global blockbuster as a locally produced new medicine.” a person in Boryung Co. said. Meanwhile, Kanarb is also booming in domestic market for its sales profit going over UUSD 10 million in just 8 months (which is the shortest period among new medicines) after introduced for the first time in new medicines for sales, and the figure grew double in last year. Moreover, Boryung Pharm. Co. has formed line-ups for these combination products and expecting an increase in market dominance. A newly developing CCB combination product is at the Phase II human clinical trial and it is expected to be released in the near future.

“R-Pharm” is one of the leading Russian high-tech pharmaceutical enterprises. Key areas of R-Pharm’s competence include: manufacturing of finished drugs and APIs, R&D of innovative medicines and technologies, training and education for industry and health care specialists, venture investments in promising scientific data and research, delivery of laboratory equipment, cooperation with major international pharmaceutical companies and international universities in the field of drug development and combined clinical trials in Russia.